Pleuropulmonary blastoma (PPB), a rare childhood neoplasm of the lung, is linked to pathogenic DICER1 variants. We investigated checkpoint inhibitor markers including Programmed Death Ligand 1 (PD-L1), PD1, CD8 and tumor mutational burden (TMB) in PPB.
Material and Methods
Cases were collected from departmental archives and the International PPB/DICER1 Registry. Immunohistochemistry (IHC) for PD-L1, PD-1, CD8 and DNA mismatch repair (MMR) genes were performed. In addition, normal-tumor paired whole exome sequencing (WES) was performed in two cases.
Results
Twenty-five PPB cases were studied, consisting of Type I (n = 8, including 2 Ir), Type II (n = 8) and Type III (n = 9). PD-L1 combined positive score (CPS) of 1, 4 and 80 was seen in three (3/25, 12.0%) cases of Type II PPB with negative staining in the remaining cases. PD-1 and CD8 stains demonstrated positive correlation (P < .05). The density of PD1 and CD8 in the interface area was higher than within tumor (P < .05). The MMR proteins were retained. TMB was 0.65 mutations/Mb in type II PPB with high expression of PD-L1, and 0.94 mutations/Mb in one negative PD-L1 case with metastatic tumor.
Conclusion
A small subpopulation of PPB patient might benefit from checkpoint immunotherapy due to positive PD-L1 staining.
MessingerYHStewartDRPriestJR, et al. Pleuropulmonary blastoma: a report on 350 central pathology–confirmed pleuropulmonary blastoma cases by the International Pleuropulmonary Blastoma Registry.Cancer. 2015;121(2):276–285.
HillDAIvanovichJPriestJR, et al. DICER1 mutations in familial pleuropulmonary blastoma.Science. 2009;325:965.
5.
PriestJRWattersonJStrongL, et al. Pleuropulmonary blastoma: a marker for familial disease. J Pediatr. 1996;128:220–224.
6.
HillDAJarzembowskiJAPriestJRWilliamsGSchoettlerPDehnerLP.Type I pleuropulmonary blastoma: pathology and biology study of 51 cases from the International Pleuropulmonary Blastoma Registry.Am J Surg Pathol. 2008;32:282–295.
7.
MessingerYHWilliamsGMPriestJR, et al. Outcome of 116 cases of pleuropulmonary blastoma type I and type Ir (regressed): a report from the International PPB Registry (IPPBR).J Clin Oncol. 2012,30S:9522.
8.
PriestJRHillDAWilliamsGM, et al. Type I pleuropulmonary blastoma: a report from the International Pleuropulmonary Blastoma Registry.J Clin Oncol. 2006;24:4492–4498.
9.
PriestJRWilliamsGMHillDADehnerLPJaffeA.Pulmonary cysts in early childhood and the risk of malignancy.Pediatr Pulmonol. 2009;44:14–30.
10.
AokiTHinoMKohK, et al. Low frequency of programmed death ligand 1 expression in pediatric cancers.Pediatr Blood Cancer. 2016;63(8):1461–1464.
11.
van DamLSde ZwartVMMeyer-WentrupFA.The role of programmed cell death-1 (PD-1) and its ligands in pediatric cancer.Pediatr Blood Cancer. 2014;62:190–197.
12.
SnyderAMakarovVMerghoubT, et al. Genetic basis for clinical response to CTLA-4 blockade in melanoma.N Engl J Med. 2014;371(23):2189–2199.
13.
SchumacherTNSchreiberRD.Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69–74.
14.
BrahmerJRTykodiSSChowLQ, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366(26):2455–2465.
15.
WagnerLMAdamsVR.Targeting the PD-1 pathway in pediatric solid tumors and brain tumors.Onco Targets Ther. 2017;10:2097–2106.
16.
SharmaPAllisonJP.The future of immune checkpoint therapy.Science. 2015;348:56–61.
17.
HamanishiJMandaiMIwasakiM, et al. Programmed cell death 1 ligand 1 and tumor-infiltrating CD8+ T lymphocytes are prognostic factors of human ovarian cancer.Proc Natl Acad Sci USA. 2007;104:3360–3365.
18.
TumehPCHarviewCLYearleyJH, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance.Nature. 2014;515:568–571.
19.
AbroBKaushalMChenL, et al. Tumor mutation burden, DNA mismatch repair status and checkpoint immunotherapy markers in primary and relapsed malignant rhabdoid tumors. Pathol Res Pract. 2019;215(6):152395.
20.
HeMAbroBKaushalM, et al. Tumor mutation burden and checkpoint immunotherapy markers in primary and metastatic synovial sarcoma. Hum Pathol. 2020;100:15–23.
21.
KulangaraKZhangNCoriglianoE, et al. Clinical utility of the combined positive score for programmed death ligand-1 expression and the approval of pembrolizumab for treatment of gastric cancer.Arch Pathol Lab Med. 2018;143(3):330–337.
22.
ChowdhuryFDunnSMitchellSMellowsTAshton-KeyMGrayJC.PD-L1 and CD8+PD1+ lymphocytes exist as targets in the pediatric tumor microenvironment for immunomodulatory therapy. Oncoimmunol. 2015;4:10.
23.
DePristoMABanksEPoplinR, et al. A framework for variation discovery and genotyping using next-generation DNA sequencing data.Nat Genet. 2011;43:491–498.
24.
CibulskisKLawrenceMSCarterSL, et al. Sensitive detection of somatic point mutations in impure and heterogeneous cancer samples.Nat Biotechnol. 2013;31:213–219.
25.
WangKLiMHakonarsonH.ANNOVAR: Functional annotation of genetic variants from next-generation sequencing dataNucl Acids Res. 2010;38:e164.
26.
ChoJHZhouWChoiYL, et al. Retrospective molecular epidemiology study of PD-L1 expression in patients with EGFR-mutant non-small cell lung cancer.Cancer Res Treat. 2018;50(1):95–102.
27.
ZhuJArmstrongAJFriedlanderTW, et al. Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. J Immunother Cancer. 2018;6(1):4.
28.
ScorerPScottMLawsonN, et al. Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay.Diagn Pathol. 2018;13(1):47.
29.
ForsterMDDevlinMJ.Immune checkpoint inhibition in head and neck cancer. Front Oncol. 2018;8:310.
30.
HanYLiuDLiL.PD-1/PD-L1 pathway: current researches in cancer. Am J Cancer Res. 2020;10(3):727–742.
31.
KawakamiFSircarKRodriguez-CanalesJ, et al. Programmed cell death ligand 1 and tumor-infiltrating lymphocyte status in patients with renal cell carcinoma and sarcomatoid dedifferentiation.Cancer. 2017;123(24):4823–4831.
32.
Sampedro-NúñezMSerrano-SomavillaAAdradosM, et al. Analysis of expression of the PD-1/PD-L1 immune checkpoint system and its prognostic impact in gastroenteropancreatic neuroendocrine tumors. Sci Rep. 2018;8:17812.
33.
BernsteinECaudyAAHammondSMHannonGJ.Role for a bidentate ribonuclease in the initiation step of RNA interference.Nature. 2001;409(6818):363–366.
34.
PughTJYuWYangJ, et al. Exome sequencing of pleuropulmonary blastoma reveals frequent biallelic loss of TP53 and two hits in DICER1 resulting in retention of 5p-derived miRNA hairpin loop sequences.Oncogene. 2014;33(45):5295–5302.
35.
BrennemanMFieldAYangJ, et al. Temporal order of RNase IIIb and loss-of-function mutations during development determines phenotype in pleuropulmonary blastoma/DICER1 syndrome: a unique variant of the two-hit tumor suppression model [version 2; peer review: 2 approved]. F1000Research. 2018;4:214.
36.
SekiMYoshidaKShiraishiY, et al. Biallelic DICER1 mutations in sporadic pleuropulmonary blastoma.Cancer Res. 2014;74(10):2742–2749.
37.
KamiharaJPaulsonVBreenMA, et al. DICER1-associated central nervous system sarcoma in children: comprehensive clinicopathologic and genetic analysis of a newly described rare tumor.Mod Pathol. 2020;33(10):1910–1921.
